The Indian Supreme Court’s rejection of Novartis’s Glivec patent brought the increasingly tense debate about the balance between patent rights and access to medicines to the forefront. Anand Grover, who successfully represented the Cancer Patient Aid Association in the case, argues that the patent system may not be the best way to encourage drug research
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
In the wake of controversy surrounding Banksy’s recent London mural, AJ Park’s Thomas Huthwaite and Eloise Calder delve into the challenges street artists face in protecting their works and rights
Alex Levkin, founder of iPNOTE, discusses reshaping the filing industry through legal tech, and why practitioners’ advice should stretch beyond immediate legal needs
In the fourth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss unconscious bias in the IP workplace and how to address it
News of Singapore planning to streamline the licensing framework for foreign law firms and a partnership between Avanci and Xprize were also among the top talking points